Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma

• Main Authors: David A. Reardon, James J. Vredenburgh, Annick Desjardins, Katherine B. Peters, Sith Sathornsumetee, Stevie Threatt, John H. Sampson, James E. Herndon, April Coan, Frances McSherry, Jeremy N. Rich, Roger E. McLendon, Steven Zhang, Henry S. Friedman
• Other Authors: Dana-Farber Cancer Institute
• Format: Article
• Published: 2018
• Subjects: Biochemistry, Genetics and Molecular Biology; Medicine; Neuroscience
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/13687
• Institution: Mahidol University

To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of dasatinib, an inhibitor of the Src family kinase proteins, with erlotinib, an e pidermal growth factor receptor tyrosine kinase inhibitor, among recurrent malignant glioma patients. Once daily dasatinib was escalated i...